Trials / Completed
CompletedNCT00604630
Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke
German Multicenter EPO Stroke Trial (Phase II/III)
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 522 (actual)
- Sponsor
- Max-Planck-Institute of Experimental Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this randomized, double-blind, placebo-controlled multicenter study is to determine in a cohort of 506 patients with acute ischemic stroke in the middle cerebral artery territory, the effect of a three-day high-dose, intravenous erythropoietin treatment on functional outcome up to a follow-up of 90 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | recombinant human erythropoietin alfa | 40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms |
| DRUG | 0.9% NaCl | 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms |
Timeline
- Start date
- 2003-01-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2008-01-30
- Last updated
- 2008-10-22
Locations
9 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00604630. Inclusion in this directory is not an endorsement.